In the last few years, morphological evaluation of tumour-infiltrating lymphocytes (TILs) in breast cancer has been proposed as a potentially useful biomarker given the prognostic value observed in triple-negative breast cancer (TNBC) [93, 94], and HER2 subtypes [93, 95]. The gene discussed is ERBB2; the disease is breast cancer.